US10889546, US2007/0299086 Table 2.1 | 1007377-58-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: US10889546, US2007/0299086 Table 2.1
• 英文别名: 2-[[3-hydroxy-5-(3-methylphenyl)pyridine-2-carbonyl]amino]acetic acid
• CAS: 1007377-58-3
• 化学式: C₁₅H₁₄N₂O₄
• 分子量: 286.287
• InChiKey: UOSRCDIDWDDSRM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  99.5
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  methyl N-(5-bromo-3-hydroxypicolinoyl)glycine 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 potassium phosphate 、 palladium on activated charcoal 、 氢气 、 lithium hydroxide 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 12.0h， 生成 US10889546, US2007/0299086 Table 2.1
  参考文献：
  名称：

  An improved and scalable synthesis of N-(5-(4-cyanophenyl)-3-hydroxypicolinoyl)glycine, a promising PHD2 inhibitor for the treatment of anemia

  摘要：

  An improved and scalable synthetic method of N-(5-(4-cyanophenyl)-3-hydroxypicolinoyl)glycine, a promising inhibitor of PHD2, is described. The optimized route staring from commercially available 5-bromo-3-nitropicolinonitrile takes only five chemical steps and has a dramatically increased total yield of 37.6% without chromatographic purifications. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2015.07.013

文献信息

• Alkynyl pyridine prolyl hydroxylase inhibitor, and preparation method and medical use thereof
  申请人：Jiangsu Hengrui Medicine Co., Ltd.

  公开号：US10889546B2

  公开（公告）日：2021-01-12

  The present invention relates to the field of pharmaceutical chemistry. In particular, the present invention relates to a class of alkynyl pyridine prolyl hydroxylase inhibitors (I). The experiments show that such a compound has good activity of inhibiting prolyl hydroxylase, and can enhance the generation and secretion of erythropoietin in cell or animal models, and thus can promote the generation of red cells, and can be used for the treatment or prevention of anemia, such as chronic kidney disease anemia, and ischemic diseases, including ischemic strokes, myocardial ischemia and other related diseases. The present invention also discloses a method for preparing such a compound.

  本发明涉及药物化学领域。特别是，本发明涉及一类炔基吡啶脯氨酰羟化酶抑制剂（I）。实验表明，该类化合物具有良好的抑制脯氨酰羟化酶的活性，在细胞或动物模型中能增强促红细胞生成素的生成和分泌，从而能促进红细胞的生成，可用于治疗或预防贫血，如慢性肾病贫血，以及缺血性疾病，包括缺血性中风、心肌缺血等相关疾病。本发明还公开了制备这种化合物的方法。
• [EN] ALKYNYL PYRIDINE PROLYL HYDROXYLASE INHIBITOR, AND PREPARATION METHOD AND MEDICAL USE THEREOF<br/>[FR] INHIBITEUR DE L'ALCYNYL PYRIDINE PROLYL HYDROXYLASE, PROCÉDÉ DE PRÉPARATION ET UTILISATION MÉDICALE DE CELUI-CI<br/>[ZH] 炔基吡啶类脯氨酰羟化酶抑制剂、其制备方法和医药用途
  申请人：UNIV CHINA PHARMA

  公开号：WO2017059623A1

  公开（公告）日：2017-04-13

  本发明涉及药物化学领域。具体涉及一类炔基吡啶类脯氨酰羟化酶抑制剂(I)。实验表明该类化合物具有良好的脯氨酰羟化酶抑制活性，可以在细胞或动物模型上增强促红细胞生成素的生成与分泌，从而可以促进红细胞的生成，可应用于治疗或预防贫血症如慢性肾病贫血以及缺血性疾病如缺血性脑卒中、心肌缺血等相关疾病。本发明还公开了该类化合物的制备方法。
• COMPOSITIONS AND METHODS FOR TREATING ANEMIA
  申请人：Akebia Therapeutics, Inc.

  公开号：EP3277270B1

  公开（公告）日：2021-10-27
• ALKYNYL PYRIDINE PROLYL HYDROXYLASE INHIBITOR, AND PREPARATION METHOD AND MEDICAL USE THEREOF
  申请人：JIANGSU HENGRUI MEDICINE CO., LTD.

  公开号：US20200407319A1

  公开（公告）日：2020-12-31

  The present invention relates to the field of pharmaceutical chemistry. In particular, the present invention relates to a class of alkynyl pyridine prolyl hydroxylase inhibitors (I). The experiments show that such a compound has good activity of inhibiting prolyl hydroxylase, and can enhance the generation and secretion of erythropoietin in cell or animal models, and thus can promote the generation of red cells, and can be used for the treatment or prevention of anemia, such as chronic kidney disease anemia, and ischemic diseases, including ischemic strokes, myocardial ischemia and other related diseases. The present invention also discloses a method for preparing such a compound.
• [EN] THERAPEUTIC METHODS USING VADADUSTAT<br/>[FR] MÉTHODES THÉRAPEUTIQUES À L'AIDE DE VADADUSTAT
  申请人：AKEBIA THERAPEUTICS INC

  公开号：WO2021087144A1

  公开（公告）日：2021-05-06

  This invention provides methods for the treatment of anemia in patients with chronic kidney disease (CKD) using vadadustat (Compound 1), including methods suitable for conversion, correction, and maintenance therapy for patients. For example, methods described herein are durable, with efficacy observed for 24-52 weeks. Methods described herein can be particularly beneficial for patients converting from a previous anemia treatment comprising administration of an erythropoietin stimulating agent (ESA) such as darbepoetin alfa (DA), CKD patients on dialysis (e.g., peritoneal dialysis or hemodialysis), or CKD patients having certain hemoglobin (Hb) levels.